Filter by

  • Publication Year
  • Availability
  • Attachment
  • Collection Type
    See More
  • General Material Designation
    See More
  • Location
    See More
  • Language
Found 6 from your keywords: subject="Diabemin"
cover
Metformin inhibits hepatitis B virus protein production and replication in hu…
Comment Share
Xun YH

Hepatitis B virus surface antigen (HBsAg) plays an important role in maintaining the tolerance and may interfere with host innate and adaptive immune responses; therefore, novel therapeutic strategies to reduce HBsAg loads in patients infected with hepatitis B virus (HBV) are emerging as an attractive but challenging issue. Metformin could regulate hepatic metabolism while the latter interacts …

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-
cover
Metformin: New Preparations and Nonglycemic Benefits
Comment Share
Fujita Y

Metformin has been widely used for over 5 decades. New preparations have been developed for possible enhancement of efficiency, tolerability, and pleiotropic nonglycemic effects. Extended-release metformin has contributed to adherence and improved gastrointestinal tolerability. Delayed-release metformin acts in the lower gastrointestinal tract and exerts glucose-lowering effects at lower plasma…

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-
cover
Metformin and metabolic diseases: a focus on hepatic aspects
Comment Share
Zheng J

Metformin has been widely used as a first-line anti-diabetic medicine for the treatment of type 2 diabetes (T2D). As a drug that primarily targets the liver, metformin suppresses hepatic glucose production (HGP), serving as the main mechanism by which metformin improves hyperglycemia of T2D. Biochemically, metformin suppresses gluconeogenesis and stimulates glycolysis. Metformin also inhibit…

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-
cover
Long-term Effects of Metformin on Diabetes Prevention: Identification of Subg…
Comment Share
Diabetes Prevention Program Research Group

We examined the effects of metformin on diabetes prevention and the subgroups that benefited most over 15 years in the Diabetes Prevention Program (DPP) and its follow-up, the Diabetes Prevention Program Outcomes Study (DPPOS).

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-
cover
Metabolic Control in Type 1 Diabetes: Is Adjunctive Therapy the Way Forward?
Comment Share
Warnes H

Despite advances in insulin therapies, patients with type 1 diabetes (T1DM) have a shorter life span due to hyperglycaemia-induced vascular disease and hypoglycaemic complications secondary to insulin therapy. Restricting therapy for T1DM to insulin replacement is perhaps an over-simplistic approach, and we focus in this work on reviewing the role of adjuvant therapy in this population.

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-
cover
Strategies for Diabetes Management: Using Newer Oral Combination Therapies Ea…
Comment Share
Zonszein J

The duration of uncontrolled type 2 diabetes mellitus (T2DM) can adversely impact small and large vessels, eventually leading to microvascular and macrovascular complications. Failure of therapeutic lifestyle changes, monotherapy, and clinical inertia contribute to persistent hyperglycemia and disease progression.

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-